von Hippel-Lindau syndrome (VHL)
Von Hippel-Lindau syndrome is an autosomal dominant tumor predisposition syndrome caused by germline pathogenic variants in the VHL tumor suppressor gene on chromosome 3p25, with >90% lifetime penetrance by age 65. Molecular pathology = HIF-2α pseudohypoxia: the VHL protein normally targets HIF-α subunits for proteasomal degradation under normoxic conditions; loss-of-function variants produce constitutive HIF-2α activity and downstream VEGF / EPO / GLUT1 overdrive, driving the tumor spectrum. Manifestations: CNS hemangioblastomas (cerebellum + brainstem + spinal cord — multiple tumors across lifespan); retinal angiomas (often first manifestation in childhood; vision-loss risk from exudation and hemorrhage); clear cell renal cell carcinoma (cumulative lifetime risk ~70%; bilateral and multifocal; LEADING CAUSE OF VHL MORTALITY); pheochromocytoma and paraganglioma (~20%, concentrated in Type 2 genotypes); pancreatic NETs and serous cystadenomas (~15-20%); endolymphatic sac tumors (cause hearing loss); epididymal or broad-ligament cystadenomas. Genotype-phenotype: Type 1 (truncating variants and large deletions — low pheo risk); Type 2 (missense — high pheo risk) subdividing into 2A (low ccRCC), 2B (high ccRCC), and 2C (pheo-only); Chuvash polycythemia is the autosomal recessive variant. Diagnostic criteria: clinical (≥1 hemangioblastoma + ≥1 visceral tumor OR ≥2 hemangioblastomas) OR pathogenic germline VHL variant. Surveillance per VHL Alliance / Stewart 2014 / NIH-Linehan-group: annual ophthalmologic + neurologic exam from infancy; annual urine catecholamines/metanephrines from age 5; annual abdominal MRI from age 16; brain/spine MRI every 2 years from age 16; audiometry every 2-3 years from age 5. Management: nephron-sparing partial nephrectomy / cryoablation / RFA / surveillance for ccRCC (3cm rule); microsurgical / Gamma Knife / observation for CNS hemangioblastomas; laser photocoagulation / cryotherapy / anti-VEGF for retinal angiomas; pheochromocytoma surgery per PPGL guidelines. **BELZUTIFAN (Welireg, Merck) FDA-approved August 2021** = first-in-class HIF-2α inhibitor for VHL-associated RCC + CNS hemangioblastoma + pancreatic NET (LITESPARK-004); FDA expanded indication December 2023 to advanced ccRCC (LITESPARK-005). Sunitinib, cabozantinib, pazopanib as multi-kinase TKI options. 177Lu-DOTATATE Lutathera PRRT for SSTR-positive pancreatic NETs = one TRUE peptide therapy in VHL portfolio. **EDITORIAL**: BPC-157 PRO-ANGIOGENIC VEGF / NO / eNOS modulation is mechanistically OPPOSITE to belzutifan's HIF-2α inhibition — the sharpest peptide contradiction in the library (Tier 2, not the usual Tier 3 contraindication ceiling). GH-axis peptides (CJC-1295, tesamorelin, ipamorelin): IGF-1 mitogenicity in multi-organ tumor-surveillance population; tesamorelin label contraindicates active malignancy (VHL routinely manages indolent tumors under surveillance). Semaglutide: coordinated-care decision given pancreatic NET surveillance overlap. NMN: no engagement with VHL HIF biology. VHL Alliance patient advocacy. Fifty-sixth deliberate non-elevation.
What changes during this transition
Von Hippel-Lindau syndrome is an autosomal dominant tumor predisposition syndrome caused by germline pathogenic variants in the VHL tumor suppressor gene on chromosome 3p25, with lifetime penetrance exceeding 90% by age 65. The molecular pathology is HIF-2α pseudohypoxia: the VHL protein normally targets HIF-α subunits for proteasomal degradation under normoxic conditions; loss-of-function variants produce constitutive HIF-2α activity and downstream VEGF / EPO / GLUT1 overdrive, driving the characteristic VHL tumor spectrum. Clinical manifestations cover multiple organ systems: CNS hemangioblastomas (cerebellum, brainstem, spinal cord — often multiple tumors across the lifespan); retinal angiomas (frequently the first manifestation in childhood, with vision-loss risk from exudation and hemorrhage); clear cell renal cell carcinoma (cumulative lifetime risk ~70%, typically bilateral and multifocal, the leading cause of VHL mortality); pheochromocytoma and paraganglioma (~20%, concentrated in Type 2 genotypes); pancreatic neuroendocrine tumors and serous cystadenomas; endolymphatic sac tumors (cause of hearing loss); and epididymal or broad-ligament cystadenomas. Genotype-phenotype correlations matter for risk stratification: Type 1 (truncating variants and large deletions) carries low pheochromocytoma risk; Type 2 (missense variants) carries high pheo risk and subdivides further into 2A (low ccRCC risk), 2B (high ccRCC risk), and 2C (pheo-only); Chuvash polycythemia is the autosomal recessive variant. Diagnostic criteria are clinical (one hemangioblastoma plus one visceral tumor, or two hemangioblastomas) or molecular (pathogenic germline VHL variant). Surveillance follows the VHL Alliance / Stewart 2014 / NIH-Linehan-group schedule: annual ophthalmologic and neurologic exam from infancy, annual urine catecholamines and metanephrines from age 5, annual abdominal MRI from age 16, brain and spine MRI every 2 years from age 16, audiometry every 2-3 years from age 5. Management is multi-organ and lifelong: nephron-sparing partial nephrectomy, cryoablation, RFA, or surveillance (the 3cm rule) for renal lesions; microsurgical resection, Gamma Knife, or observation for CNS hemangioblastomas; laser photocoagulation, cryotherapy, or anti-VEGF for retinal angiomas; pheochromocytoma surgery per PPGL guidelines. The therapeutic landscape changed materially in August 2021 when the FDA approved BELZUTIFAN (Welireg, Merck), a first-in-class HIF-2α inhibitor, for VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors — directly targeting the molecular driver of the disease; the indication was expanded December 2023 to advanced ccRCC on the LITESPARK-004 and LITESPARK-005 trial program. Multi-kinase TKIs (sunitinib, cabozantinib, pazopanib) remain options. The one TRUE peptide therapy in the VHL portfolio is 177Lu-DOTATATE (Lutathera) peptide receptor radionuclide therapy for SSTR-positive pancreatic NETs in selected patients. The community peptide space is editorially uncomfortable for VHL across the board: pro-angiogenic VEGF / eNOS modulators (BPC-157 archetype) are mechanistically opposite to belzutifan's HIF-2α inhibition; GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) raise IGF-1 in a multi-organ tumor-surveillance population where tesamorelin's label contraindicates active malignancy; GLP-1 agonists (semaglutide) interact with pancreatic NET surveillance; NAD+ precursors (NMN) don't engage with VHL biology at all. Care is delivered through VHL multidisciplinary teams (NIH-Linehan-group model), with the VHL Alliance serving as the primary patient advocacy organization. Editorial substrate exists on this page to give honest answers when users ask whether community peptides fit into VHL care; the answer is consistent across the candidates surveyed: not without explicit multidisciplinary team approval, and in the BPC-157 case, the mechanistic asymmetry is sharp enough that the editorial position is non-engagement rather than 'discuss with your team.'
Important caveat
VHL is managed by a multidisciplinary team (typically NIH-Linehan-group model): urologic oncology + neurosurgery + ophthalmology + endocrinology + medical genetics. **CHILDHOOD-ONSET SURVEILLANCE BURDEN**: annual ophthalmologic + neurologic from INFANCY; annual urine catecholamines/metanephrines from age 5; abdominal MRI annual from age 16; brain/spine MRI every 2y from age 16; audiometry every 2-3y from age 5. Family screening obligations begin in infancy. **ccRCC IS LEADING CAUSE OF MORTALITY**: ~70% lifetime risk, bilateral and multifocal — nephron-sparing surgery / cryoablation / RFA / surveillance (3cm rule) is the management paradigm; missed surveillance has lifelong consequences. **RETINAL ANGIOMAS** can cause childhood vision loss from exudation/hemorrhage — laser, cryotherapy, anti-VEGF intervention timing matters. **BELZUTIFAN (Welireg) FDA Aug 2021** is the FDA-approved HIF-2α inhibitor for VHL-associated RCC + hemangioblastomas + pNETs; FDA expanded Dec 2023 to advanced ccRCC. Multi-kinase TKIs (sunitinib, cabozantinib, pazopanib) remain options. **BPC-157 IS TIER-2 MECHANISTICALLY CONTRADICTED**: its pro-angiogenic VEGF / NO / eNOS modulation is the EXACT OPPOSITE direction of belzutifan's HIF-2α inhibition in the same disease. This is not theoretical extrapolation; it is the FDA-approved therapy and the candidate peptide pulling on opposite ends of the same HIF-2α / VEGF axis. The editorial position is non-engagement, not 'discuss with your team.' **GH-AXIS PEPTIDES (CJC-1295, tesamorelin, ipamorelin, sermorelin, MK-677)**: IGF-1 mitogenicity in a population carrying lifetime cumulative cancer risk approaching certainty (ccRCC ~70%, hemangioblastomas, retinal angiomas, pancreatic NETs, pheo/PGL in Type 2). Tesamorelin FDA label contraindicates active malignancy — and VHL patients are routinely managing tumors under surveillance (3cm-rule observation for renal lesions, watchful waiting for asymptomatic hemangioblastomas), gray-zone territory the label was not written for. Treat as one decision across the GH-axis class. **SEMAGLUTIDE / GLP-1 AGONISTS**: coordinated-care decision, not absolute contraindication — but pancreatic NET surveillance (annual abdominal MRI from age 16) interacts with GLP-1 pancreatic islet biology + pancreatitis-signal concerns, and any new pancreatic finding gets interpreted against a known GLP-1 exposure rather than as unexplained progression. Disclose BEFORE the weight-loss / diabetes prescriber starts it. **NMN**: no engagement with VHL HIF biology; not disease-modifying; doesn't displace surveillance adherence + family screening conversations. **177Lu-DOTATATE LUTATHERA** is the one TRUE peptide therapy in VHL portfolio — SSTR-positive metastatic pancreatic NETs; delivered by NET-experienced oncology, not peptide clinics. **GENOTYPE MATTERS**: Type 1 (truncating, low pheo) vs Type 2A/2B/2C (missense, high pheo, varying ccRCC) vs Chuvash polycythemia (autosomal recessive variant) shapes surveillance + management decisions. **PHEOCHROMOCYTOMA OVERLAP** (~20%, Type 2 concentrated): if pheo is present, see also the pheochromocytoma life-stage entry — perioperative preparation (alpha-blockade ≥10-14 days, fluid loading, beta only after alpha) is load-bearing. VHL Alliance is patient-side advocacy. Stewart 2014 + NIH-Linehan group are reference standards. WADA athletes: peptide GH secretagogues prohibited at all times. Pregnancy is high-risk; coordinate VHL team + maternal-fetal medicine + REI; preimplantation genetic testing options for cascade-affected family planning.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.